Select country change
Shopping cart (0 , 0,00 ) Menu Search


MicroRNAs (miRNAs) are new and promising potential biomarkers for diagnosis and prognosis of many diseases, which opens up a new field of goals and challenges for the BioVendor R&D team. Development of miRNA diagnostic assays is just the first step; our mission is to provide validated kits to measure individual miRNAs or diagnostically relevant miRNA “groups” supported with tools for standardized miRNA isolation, sample collection, and pretreatment.


MicroRNAs (miRNAs) are small, non-coding RNA molecules typically containing ~22 nucleotides found in human, animals, plants and some viruses which are playing an important regulatory role in the gene translation via silencing or degradation of target mRNAs. During the RNA silencing, miRNA functions as a complementary guide which binds with its target mRNAs, followed by action of AGO proteins family which works as effectors by recruiting factors that induce translational repression, mRNA deadenylation and mRNA decay. (Minju Ha, Nature Reviews, 2014)

MicroRNAs (miRNAs) are involved in virtually all physiologic processes, including differentiation and proliferation, metabolism, hemostasis, apoptosis or inflammation. The biogenesis and function of miRNAs are tightly regulated, and their dysregulation is often associated with pathology of many diseases such as cancer, heart disease or neurological disorders. Recently, the miRNA has been proposed as powerful biomarker for prediction of the diseases, treatment response or prediction of progression.


miRNA Quantification Method

miRNA Quantification Method

miRia – miRNA immunoassay

Novel method for miRNA quantification based on immunoassay. The novel method involves hybridization of miRNA isolated from patient sample to complementary biotinylated DNA oligonucleotide probe followed by monoclonal antibody detection of perfectly matched DNA/miRNA hybrids in several different arrangements and possible methods of visualization:

  • Colorimetric – miReia – miRNA enzyme immunoassay
  • Chemiluminescent – miRacle – miRNA antibody/capture luminometry

Click to see flyer about miRNA quantification


miREIA (miRNA Enzyme Immunoassay) – a novel, immunoassay-based method of miRNA quantification

miRNA isolated from a patient sample is hybridized to complementary biotinylated DNA oligonucleotide probe.

The DNA/RNA hybrids are then processed in the manner of ELISA in a microtiter plate coated with a monoclonal antibody specific to perfectly matched DNA/miRNA hybrids.

After washing, the solid phase is incubated with streptavidin-HRP conjugate and the resulting complexes are visualized (after another washing step) by a chromogenic substrate.

The miREIA exhibits superior analytical specificity, limit of detection as low as 0.1 attomol/μl miRNA, excellent analytical characteristics and strong correlation with the qRT-PCR method (Pearson correlation coefficient >0.9).

miREIA can be run on common immunoassay analyzers, is compatible with standard clinical workflow, does not require amplification steps and results are obtained in less than three hours including miRNA profiling.

The assay arrangement:

  • Classical ELISA format
  • Array format
  • Luminex beads format



miREIA vs. RT-qPCR

miREIA vs. RT-qPCR

Reverse transcription reaction NOT required Required
Amplification steps NOT required Required
Total time to result 2 hours  >3 hours
Quantification Absolute (attomol/μl) Relative
Instrumentation required Immunoassay equipment  Specific PCR cycler
Cost per sample Lower Higher


New miREIA kits

New miREIA kits


hsa-miR-21-5p miREIA (Cat. No: RDM0001H)

hsa-miR-21-5p is a typical onco-miRNA frequently upregulated in solid tumors, most of the targets are tumor suppressors. Pancreatic, colorectal, gastric, brain, breast, lung, esophageal and hepatocellular cancers were often associated with miR-21-5p. It also plays role in the development of cardiovascular disease, acute myocardial infarction, pulmonary diseases and in regulation of immunological and developmental processes. Besides in tissues, recent evidence indicates the presence of miR-21-5p in various types of extracellular fluid, such as plasma, serum, CSF, saliva, gastric juice, pancreatic juice, sputum, and pancreatic cyst fluid. 


Click to see the product brochure hsa-miR-21-5p miREIA kit


hsa-miR-93-5p miREIA (Cat. No: RDM0002H)

hsa-miR-93-5p is an onco-miRNA. Up-regulation of miR-93-5p is correlated with worse clinic-pathological features and can serve as an independent marker for poor prognosis in patients with non-small cell lung cancer. NSCLC cell proliferation, migration, and invasion were significantly stimulated by miR-93-5p upregulation and inhibited by miR-93-5p downregulation. miR-93-5p was also up-regulated in non-muscle invasive bladder cancer.Increased expression of circulating miR-93-5p in women with polycystic ovary syndrome may represent a novel non-invasive biomarker for diagnosis.

hsa-miR-145-5p miREIA (Cat. No: RDM0003H)

hsa-miR-145-5p might constitute a promising molecular marker for renal cell carcinoma classification and staging. It was described as a prognostic biomarker of overall survival in colon cancer but as a tumor suppressor gene in NSCLC metastasis.Low expression and plasma levels were found in patients with coronary artery disease and acute myocardial infarction.

hsa-miR-150-5p miREIA (Cat. No: RDM0004H)

hsa-miR-150-5p is linked with number of cancers. It was up-regulated in plasma of melanoma patients. Findings also demonstrate miR-150-5p as a putative novel biomarker of inflammatory active disease with the potential to be used for early diagnosis of multiple sclerosis. miR-150-5p is downregulated in children with tuberculosis. In aplastic anemia, levels of miR-150-5p were elevated, compared to healthy controls.miR-150-5p is expressed in the lymph nodes, spleen and thymus and it is highly up-regulated during lymphocyte maturation and down-regulated during the activation of mature B and T cells. In vivo studies show that miR-150 is released in the external environment after T cell activation and this may cause an increase of its blood levels during immune system stimulation. 

hsa-miR-191-5p miREIA (Cat. No: RDM0005H)

hsa-miR-191-5p is dysregulated in many types of cancers (>20) and various other diseases like T2DM, pulmonary hypertension, Crohn’s and Alzheimer’s diseases. miR-191-5p regulates important cellular processes such as cell proliferation, differentiation and apoptosis. miR-191-5p is a promising disease biomarker and therapeutic target. 

hsa-miR-451a miREIA (Cat. No.: RDM0006H)

hsa-miR-451a-5p levels are differentially expressed in patients with nonalcoholic fatty liver disease, rheumatoid arthritis, diabetes and several types of cancer including renal cell carcinoma, nonsmall lung cancer, osteosarcoma, esophageal adenocarcinoma and epithelial ovarian cancer. It is overexpressed in endometriotic lesion tissue and is also associated with endometriotic lesion survival.miR-451a-5p is expressed in the circulation, predominantly by erythrocytes, where i tis proposed to play a role in the differentiation and/or maturation of red blood cells.

Coming Soon

  • hsa-miR-15a-5p miREI(Cat. No: RDM0007H)
  • hsa-miR-16-5p miREIA (Cat. No: RDM0008H)
  • hsa-miR-23a-3p miREIA (Cat. No: RDM0009H)
  • hsa-miR-197-3p miREIA (Cat. No: RDM0010H)
  • hsa-miR-320a miREIA (Cat. No: RDM0011H)
  • hsa-miR-24-3p miREIA (Cat. No: RDM0012H)
  • hsa-miR-142-5p miREIA (Cat. No: RDM0013H)
  • hsa-miR-222-3p miREIA (Cat. No: RDM0014H)
  • hsa-miR-223-3p miREIA (Cat. No: RDM0015H)
  • hsa-miR-499a-5p miREIA (Cat. No: RDM0016H)
Scientific Presentations

Scientific Presentations

Posters presented at scientific congresses

May 2018:
EAS 2018 (Lisbon, Portugal)
- poster Novel immunoassay approach to investigate microRNA biomarkers in acute myocardial infartion

April 2018:
AACR 2018 (Chicago, USA) - poster New clinical diagnostic approach for miRNA quantification using the Chlorella virus DNA ligase

May/June 2017:
RNA society congress 2017 (Prague, Czech Republic) - poster miRiam – NEW TRENDS IN microRNA QUANTIFICATION

April 2017:
85th EAS congress 2017 (Prague, Czech Republic) - e-poster MicroRNA-BASED DIAGNOSTICS IN CARDIOVASCULAR DISEASE

October 2016:
GTCbio: Biomarker Summit Europe 2016 - 5th Biomarkers in Diagnostics Conference (Berlin, Germany) - poster miRiam – THE NEW INSIGHT INTO miRNA QUANTIFICATION


Do you want to know more?

Click to download the poster on microRNA and Cardiovascular Disease.


 Are you interested in receiving email about the news and events?

Contact us at